CWM
ABBV icon

Compass Wealth Management’s AbbVie ABBV Stock Holding History

Compass Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.5M Sell
25,828
-300
-1% -$64.5K 1.23% 25
2026
Q1 		$5.68M Sell
26,128
-1,472
-5% -$327K 1.4% 26
2025
Q4 		$6.31M Sell
27,600
-1,230
-4% -$280K 1.57% 21
2025
Q3 		$6.68M Buy
28,830
+50
+0.2% +$10.2K 1.49% 19
2025
Q2 		$5.34M Sell
28,780
-45
-0.2% -$8.36K 1.27% 25
2025
Q1 		$6.04M Sell
28,825
-747
-3% -$145K 1.54% 14
2024
Q4 		$5.25M Buy
29,572
+1,449
+5% +$266K 1.27% 23
2024
Q3 		$5.55M Sell
28,123
-1,211
-4% -$226K 1.31% 25
2024
Q2 		$5.03M Buy
29,334
+710
+2% +$118K 1.24% 27
2024
Q1 		$5.21M Buy
28,624
+580
+2% +$100K 1.3% 22
2023
Q4 		$4.35M Buy
28,044
+2,915
+12% +$425K 1.21% 26
2023
Q3 		$3.75M Buy
25,129
+1,363
+6% +$200K 1.18% 30
2023
Q2 		$3.2M Sell
23,766
-252
-1% -$37K 0.97% 39
2023
Q1 		$3.83M Sell
24,018
-635
-3% -$97.1K 1.22% 29
2022
Q4 		$3.98M Buy
+24,653
New +$3.78M 1.31% 24

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Compass Wealth Management's ABBV Position: Q2 2026 in Review

Compass Wealth Management reduced its AbbVie (ABBV) stake by 1.1% in Q2 2026, selling an estimated $64.5K and leaving 25,828 shares worth $6.5M. The position accounts for 1.23% of the portfolio, ranked #25.

Compass Wealth Management first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. The position peaked at $6.68M in Q3 2025. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Compass Wealth Management held 25,828 shares of AbbVie worth $6.5M as of Q2 2026.
  • Compass Wealth Management sold 300 AbbVie shares in Q2 2026, an estimated $64.5K.
  • AbbVie made up 1.23% of Compass Wealth Management's portfolio in Q2 2026, its #25 holding.
  • Compass Wealth Management first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • Compass Wealth Management's AbbVie position peaked at $6.68M in Q3 2025.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Compass Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.